NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.

Nepafenac

Last Revision: December 3, 2018.

Estimated reading time: 1 minute

CASRN: 78281-72-8

Chemical structure

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of nepafenac during breastfeeding. Maternal use of nepafenac eye drops would not be expected to cause any adverse effects in breastfed infants. To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Ophthalmic) Ketorolac

Substance Identification

Substance Name

Nepafenac

CAS Registry Number

78281-72-8

Drug Class

  • Breast Feeding
  • Lactation
  • Analgesic Agents
  • Nonsteroidal Antiinflammatory Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Copyright Notice

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Bookshelf ID: NBK500958PMID: 30000017